National Research Stock Crosses 200-Day Average, Time to Sell?

Analysts downgrade healthcare analytics firm as stock price rises above long-term trend

Apr. 18, 2026 at 6:51am

Got story updates? Submit your updates here. ›

An extreme close-up of the internal components and gears of a financial data terminal, conveying the intricate, industrial nature of modern finance and data analytics without using any text or logos.The rise in National Research's stock price above its 200-day moving average highlights the complex, data-driven nature of modern finance.Lincoln Today

Shares of National Research Corporation (NASDAQ:NRC), a healthcare analytics and performance improvement company, have crossed above their 200-day moving average, prompting some analysts to recommend selling the stock. The company, headquartered in Lincoln, Nebraska, provides patient and employee experience measurement tools to over 1,600 hospitals and 12,000 care sites across the U.S. and Canada.

Why it matters

Crossing above the 200-day moving average is often seen as a technical signal that a stock's long-term trend may be shifting. In the case of National Research, the stock's rise has caught the attention of analysts, who have downgraded the shares to a 'Sell' rating, citing concerns about the company's valuation and growth prospects.

The details

National Research shares closed at $18.03 on Friday, up from a 200-day moving average of $16.17. The company's stock has a market cap of $410.18 million and trades at a price-to-earnings ratio of 36.06. Analysts at Weiss Ratings recently downgraded the stock from a 'hold (c-)' rating to a 'sell (d+)' rating, citing the stock's valuation and the potential for slower growth in the healthcare analytics market.

  • National Research shares crossed above their 200-day moving average on Friday, April 18, 2026.
  • Weiss Ratings downgraded the stock from 'hold (c-)' to 'sell (d+)' on Friday, March 6, 2026.

The players

National Research Corporation

A healthcare analytics and performance improvement company that provides patient and employee experience measurement tools to over 1,600 hospitals and 12,000 care sites across the U.S. and Canada.

Weiss Ratings

An independent financial ratings agency that provides research and analysis on stocks, mutual funds, and other financial products.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if National Research's stock price can maintain its momentum above the 200-day moving average, or if it will retreat back below this key technical level.

The takeaway

The rise in National Research's stock price above its 200-day moving average has caught the attention of analysts, who are now recommending that investors consider selling the shares due to concerns about the company's valuation and growth prospects in the healthcare analytics market.